Foghorn therapeutics to participate at the h.c. wainwright bioconnect investor conference

Cambridge, mass., april 25, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at the h.c. wainwright bioconnect investor conference, which is taking place may 2, 2023, at the nasdaq headquarters in new york city. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking